Property | Value |
?:abstract
|
-
Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is currently in a pandemic outbreak and has become a global health issue. In addition to primarily involving the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1016/j.hjc.2020.12.004
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/d72cd8517a8b8414364032da72e0e2fd1c8d51d3.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7722500.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
|
?:type
|
|
?:year
|
|